2. UroToday Home
  3. Video Lectures

Prostate Cancer Translational Research

Pathogenic Variants and Prostate Cancer Germline Risk in African Ancestry - Vanessa Hayes
Degrader Therapy Tests Efficacy Against Advanced Prostate Cancer in Preclinical Studies - Jie Luo
Targeting the Regulator PTGES3 to Suppress Androgen Receptor in Resistant Prostate Cancer - Haolong Li
STAMPEDE Trial Biomarker Analysis for Advanced Prostate Cancer Treatment - Emily Grist
Baseline Biomarker Explored for Predicting Response to Neoadjuvant Hormone Therapy in Prostate Cancer - Adam Sowalsky
CYP17-Independent Androgen Biosynthesis Pathway Explored in Prostate Cancer - Nima Sharifi
PROX1 Explored as a Driver of Neuroendocrine Prostate Cancer Progression - Varadha Balaji Venkadakrishnan
EZH2 Suppression and Lineage State Evolution in Prostate Cancer - David Goodrich
Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver - Shiqin Liu
Investigational All-in-One CAR T-Cell Platform for Prostate Cancer - Nour Shobaki
GTB-5550: A Tri-specific NK Cell Engager Designed to Target B7-H3 - Nicholas Zorko
Preclinical Study Evaluates p300 Protein in AR-Driven Prostate Cancer - Jie Luo
Targeting NSD2 to Reverse Treatment Resistance in Advanced Prostate Cancer - Jia Li
Cholesterol Metabolism Pathway in Prostate Cancer Models - Daniel Frigo
Ecological Paths to Cancer Therapy Resistance and Failure - Sarah Amend
MYC Inhibitor Sensitivity and Mitochondrial Gene Expression in Cancer - Sarki Abdulkadir
FOXA2 in Neuroendocrine Prostate Cancer Transformation - Jindan Yu
Genomic Associations with Phenotypic Heterogeneity in Advanced Prostate Cancer - Michael Haffner
MMS22L Gene Mutation and Increased Prostate Cancer Risk - Jianfeng Xu & William Isaacs
Differences in Genomic Alteration Frequencies by Race in Metastatic Prostate Cancer - Kara Maxwell
Gaps in Quality of Multilingual Prostate Cancer Genetic Resources - Stacy Loeb
SEER Database Analysis of Rural vs. Urban Survival in Metastatic Prostate Cancer - Liang Qu
Large-Scale Whole Genome Sequencing Study of Localized Prostate Cancer Tumors - Paul Boutros
Evaluation of Bifunctional Immunocytokines for Solid Tumor CAR T-Cell Therapy - John Murad
Analysis of FOXA1 Alterations Across Prostate Cancer Stages - Abhijit Parolia
Analysis of PROX1 Expression in Androgen Receptor-Independent Prostate Cancer - Joshi Alumkal
m6A RNA Modifications Define Five Aggressive Prostate Cancer Subtypes - Housheng Hansen He & Xin Xu
Cholesterol Synthesis Fuels Androgen Growth in SPOP/CHD1-Altered Prostate Tumors - Di Zhao
LIG1 Deficiency Sensitizes Prostate Cancer to PARP Inhibitors - Francesca Lorenzin & Giulia Fracassi
Pathology Workup for Metastatic CRPC: Focus on Neuroendocrine Transformation - Himisha Beltran
Urinary and Gut Microbiome Contribute to Androgen Production in Cancer Patients - Karen Sfanos & Jason Ridlon
Circular RNA RMST Drives Neuroendocrine Transdifferentiation in Prostate Cancers - Housheng Hansen He, Mona Teng & Xin Xu
Trial Translator Platform Assesses Real-World Applicability of Cancer Clinical Trials - Ravi Parikh
Understanding AR-V7 Transcriptional Condensates in Advanced Prostate Cancer Models - Nada Lallous
CDK12 Loss Drives Prostate Cancer Progression and Creates Therapeutic Vulnerability - Jean Tien
ONECUT2 Crystal Structure Reveals Potential for Targeted Prostate Cancer Therapy - Brad Gallent
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes - Marina Sharifi
Dietary Pro-Oxidant Menadione in Prostate Cancer Treatment - Lloyd Trotman
Androgen Receptor Inhibition and MHC Class 1 Expression in Prostate Cancer - Lisa Chesner
Evolutionary Insights into Cancer Prevalence Across Animal Species - George Butler
SPP1 Macrophages and Immunotherapy Resistance in Advanced Prostate Cancer - Aram Lyu
Revisiting HER2 as a Therapeutic Target in Prostate Cancer - Nicole Mavingire
Lineage-Specific EZH2 Activity in Advanced Prostate Cancer Subtypes - Varadha Balaji Venkadakrishnan
Intratumoral Heterogeneity Drives Therapy Resistance in Metastatic Prostate Cancer - Laura Sena
Canonical Androgen Response Elements in Prostate Cancer Growth Suppression - Christopher Barbieri
ADT Remodels the Tumor Microenvironment from Immunologically Cold to Hot - Matthew Dallos
ASCL1 and FOXA2 in Neuroendocrine Prostate Cancer - Shaghayegh Nouruzi
CDK12 Mutation Types and PARP Treatment Effectiveness - Jonathan Chou
PARP Inhibitor Resistance Mechanisms in Prostate Cancer - Johann De Bono
AR EcDNA Discovery in Advanced Prostate Cancer Study - George Zhao
Machine Learning Stemness Signature for Prostate Cancer - Agustina Sabater & Geraldine Gueron
AR Enhancer Amplification and SSTR1 Downregulation in mCRPC - Xiaolin Zhu
Study Uncovers AR-Positive Stromal Cells’ Role in Prostate Cancer Microenvironment - Ece Eksi
MYC’s Role in Prostate Cancer Immune Suppression and Progression - Mindy Kim Graham
The Proteogenomics of Prostate Cancer Radioresistance - Roni Haas
Study Reveals How Prostate Cancer Alters Bone Structure, Increasing Fracture Risk - Felipe Eltit Guersetti
Coagulation Factor X Promotes Resistance to Androgen-Deprivation Therapy in Prostate Cancer - Bianca Calì
Heterogeneous Genetic Architectures of Prostate Cancer Susceptibility in Sub-Saharan Africa - Timothy Rebbeck
Polyaneuploid Cancer Cells Drive Metastasis and Resist Treatments in Prostate Cancer - Sarah Amend
Trial Library Platform Expands Clinical Trial Access for Patients - Hala Borno
Single-Cell Analysis Reveals Heterogeneity in Treatment-Resistant Prostate Cancer - Samir Zaidi
Notch Signaling Suppresses Neuroendocrine Differentiation in Advanced Prostate Cancer - Sheng-Yu Ku
Elevated CBP/p300 Expression Linked to Poor Outcomes in Advanced Prostate Cancer - Ayesha Shafi
Comprehensive Atlas Details Prostate Cancer Chromatin Patterns - Raunak Shrestha
Olaparib Effective in BRCA2-Altered Biochemical Recurrence Post-Prostatectomy in Phase 2 Study - Catherine Handy Marshall
Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
NSD2's Role in Prostate Cancer: Uncovering AR's Functional Duality - Abhijit Parolia
AI-Powered Prostate Cancer Grading Predicts Active Surveillance Outcomes - Cornelia Ding
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
BRCA2 and Beyond: Unraveling Genetic Drivers of Prostate Cancer Aggressiveness - Hiba Khan
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
The Future is Female: Urology Workforce Projection from 2020 to 2057 - Catherine Nam
ZNF397 Deficiency: A Key Driver of Lineage Plasticity in Prostate Cancer Therapy Resistance - Ping Mu
Advancing Prostate Cancer Research: The MDA PCa PDX Program - Estefania Labanca
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems - Isla Garraway
Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083 in Prostate Cancer - Jelani Zarif
Moonshot Initiative Funds Study on PSA-Based Risk-Stratified Prostate Cancer Screening - Siobhan Sutcliffe
Non-Invasive Detection of Neuroendocrine Prostate Cancer Through Targeted Cell-Free DNA Methylation - Himisha Beltran & Francesca Demichelis
HSD3B1 Adrenal-Permissive Allele Linked to Worse Prostate Cancer Outcomes in VA Health System Study - Rana McKay
Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes - Nicholas Zorko
Representation Matters: Trust in Digital Health Information Among Black Patients with Prostate Cancer - Stacy Loeb
Prostate Cancer Risk Variants Identified in Expanded Multi-Ancestry GWAS Meta-Analysis - Anqi Wang
Novel Computational Approach Identifies NME2-MYC Axis as Biomarker and Therapeutic Target in Enzalutamide-Resistant CRPC - Antonina Mitrofanova
Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova
Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer - Alexander Wyatt
Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda
Prostate Cancer Cell Metabolism Dictates Differentiation and Therapy Response - Andrew Goldstein
Targeting Myeloid Chemotaxis to Reverse Prostate Cancer Therapy Resistance - Johann De Bono
How UBE2J1 Impacts Anti-Androgen Resistance in Prostate Cancer - Ping Mu
Study Reveals African Ancestry Gene Variant Strongly Linked to Highly Aggressive Forms of Prostate Cancer - Mayuko Kanayama
Research Reveals How Metabolic Rewiring Enables "Persister" Cancer Cells to Resist Death and Treatment - Asmaa El-Kenawi
Novel Research Illuminates How CXCR7 Protein Interactions Promote Growth of Neuroendocrine Prostate Cancer - Jindan Yu
Decoding the Metabolic Shift Behind Prostate Cancer Drug Resistance - Andrew Goldstein
How Chemotherapy Drives Metastasis By Causing Tumor Cells to Become Significantly More Mobile - Sarah Amend
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
The Complex Web of SPOP Mutations and STING1 Signaling in Prostate Cancer - Patrick Pilié
Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor
The Hidden Mechanisms Behind Rapid Tumor Evolution: AR Amplification on Extrachromosomal DNA I Prostate Cancer - Scott Dehm
Strategically Targeting Lactate in Prostate Cancer: Clinical Insights into Tumor Control and the Development of Next-Generation Therapeutics - Akash Patnaik
AI-Based PTEN Loss Assessment: A Multicenter Retrospective Study on Prostate Cancer Metastasis - Tamara Jamaspishvili
Intrapatient Heterogeneity in Prostate Cancer: A Deep Dive into Androgen Receptor Alterations - Gerhardt Attard
Decoding the Complex Interplay of Hormone Therapy and Lineage Plasticity in Prostate Cancer - Amina Zoubeidi
The Impact of 'Sneaky Testosterone' on Post-Prostatectomy Treatment - Nima Sharifi
Translational Regulation in Prostate Cancer: The Akt/mTOR and MNK/eIF4E Pathways Unveiled - Daniela Brina
Club-Like Cells in Proliferative Inflammatory Atrophy of the Prostate - Karen Sfanos
The Role of Healthy Lifestyles in Prostate Cancer - June Chan & Rebecca Graff
Comprehensive Genomic Profiling and Treatment Patterns Across Ancestries in Advanced Prostate Cancer - Brandon Mahal
Predicting Prostate Cancer Molecular Subtype with Deep Learning on Histopathologic Images - Tamara Lotan
Loss of SYNCRIP Unleashes APOBEC-Driven Mutagenesis, Tumor Heterogeneity and AR-Targeted Therapy Resistance in Prostate Cancer - Ping Mu
Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry - Burcu Darst
A Mechanism of Tumor Suppression: Unveiling Transcription-Translation Conflict - Andrew Hsieh
Targeting Advanced Prostate Cancer with STEAP1 Chimeric Antigen Receptor T Cell and Tumor-Localized IL-12 Immunotherapy - John Lee
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer - David Quigley
The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
Unlocking Prostate Cancer Therapeutics: The Potential of Minor Spliceosome Inhibition - Mark Rubin
Targeting Tumor-Induced Neutrophil Senescence: A Novel Approach to Treating Prostate Cancer - Arianna Calcinotto & Nicolo Bancaro
Investigating the Role and Therapeutic Potential of B7-H3 in Prostate Cancer - Christina Guo
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes - Gavin Ha
Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies - Di Zhao
Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm Phase 2 Trial - Eugene Shenderov
Unveiling the Role of Rb Gene in Prostate Cancer: BET Inhibitors and Immunotherapy - Akash Patnaik
PSMA Expression in Advanced Prostate Cancer: Implications for Targeted Therapies -Himisha Beltran
Exploring PSMA Expression Variations in Metastatic Prostate Cancer: The Role of Reversible Epigenetic Changes - Michael Haffner
Breaking Down Barriers: Feasibility of Internet-based Genetic Testing for Men with Metastatic Prostate Cancer, The GENTleMEN Study -Heather Cheng
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
Elucidating Mechanisms of Resistance to ADT/PI3K-AKT Blockade in PTEN-Deficient mCRPC - Akash Patnaik
Dissecting the Dynamics of the Tumor Microenvironment: Nutrient Availability and Treatment Outcomes - Asmaa El-Kenawi
Biology and Prostate Cancer: Elucidating Differential Androgen Receptor Cistromes in African American vs. European American Men - Jacob Berchuck
ctDNA: A New Window into Prostate Cancer's Progression and Chronology of Treatment-Resistance - Alexander Wyatt
Genomic Comparison Between African American Men & European American Men with Prostate Cancer - Isra Elhussin